If you are working on the design of a high content screen that you think could utilise a BioStatus product then please contact us to discuss your requirements. We will offer you scientific advice and take advantage of the knowledge gained through citations of our products in more than 10,000 peer-reviewed journal articles.
BioStatus products have been utilised in high content screens for 2D and 3D assay systems by major pharmaceutical companies, research institutes and academic laboratories around the globe for more than 18 years. The first verified use of DRAQ5 in a screen was in 2003 at Astra Zeneca's Charnwood site!
BioStatus personnel have participated actively in high content screening scientific conferences throughout its history: SBS (later SLAS), CHI's High Content Analysis, ELRIG's "Drug Discovery" and "Pharmaceutical Flow Cytometry and Imaging", SBI2's "High Content" annual conference, workshops at ICCB and Experimental Biology amongst many others and contributed to a number of training courses.
First, we want to make sure that you use the right product and we will communicate with you the details for its place in your protocol and how it might be analysed on your high content platform. If we don't think it's right for you we will tell you - your success is always the priority for us.
Once you've tested it at bench-scale and are confident it is transferable to your high content platform we can together consider the bulk quantity required and the discount that would apply along with the best package/presentation/schedule.
Significant discount is available for bulk purchases of multiple millilitre single order purchases and for repeat, call-off and standing orders - we are flexible to your needs.
Once everything is agreed we will make sure that you have your shipment of a single lot number of product well in advance of the start and, if requested, we would be delighted to supply a test vial of that same lot number for your pilot experiment along with your purchase (as a matter of best practice).
Contact us - let's start the discussion!
No comments :
Post a Comment